Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MedMira Inc V.MIR

Alternate Symbol(s):  MMIRF

Healthcare Medical Devices
MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.


TSXV:MIR - Post by User

MedMira Inc
Bullboard Posts
User Avatar Image
(26)
•••
Post by Schmidon Jun 21, 2020 2:34pm
495 Views
Post# 31174561

MIR Website FDA & CE packaging inserts both claim

MIR Website FDA & CE packaging inserts both claim 97.1% & 100% CE Mark means Europeon Union, so don't mix that EU with emergency use.  Dog walker is just trying to create doubt and fear, his intent obvious.

1.3. Venous Whole Blood Samples. Thirty-seven (37) SARS-CoV-2 negative whole blood samples (collected in K2 EDTA tubes) were assessed with REVEALCOVID-19TM Total Antibody Test prior to studies. Blood specimens were then fractionated and ~300µL of plasma from each was exchanged for the RT-PCR confirmed SARS-CoV-2 positive plasma samples. Positive Negative Positive Negative Clinical Truth REVEALCOVID-19TM Total Antibody Test 36 1 0 37 PPA = 97.1% NPA = 100.0%

One false negative in 37 tests  Zero false positives in 37 tests = 100% reliable 

USA Packaging Insert

CE Packaging Insert
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities